Clinical Trial Search

Primary: Percent of Participants With Locoregional Control of Treating Brain Metastasis Patients — 92; 98.6; 46; 46 percentage of participants

Primary: Proportion of Patients Dying of Neurological Death, Defined as Dying With Progressive Neurological Dysfunction Regardless of Systemic Disease Status — 5 patients

Primary: Affects of Response Rate of Chemotherapy With Intra-arterial Carboplatin and Oral Temozolomide — 42.8 percentage of patients with response

Primary: Objective Response Rates. Assessed With Cranial MRI — 78.6; 48.1 Percentage of participants with OR — p=0.019

Primary: Local Control — 13; 23; 2; 1 participants

Primary: Percentage of the Gross Tumor Volume With a BTB Opening of Ktrans > 0.005 Min-1 — 78.6; 85.6; 6.4; 74.4 percentage of gross tumor volume

Primary: The Average Time From HBO Chamber Exit to SRS beam-on — 8.3 minutes

Primary: Neurocognitive Progression as Measured by the Number of Participants With Cognitive Deterioration by 3 Months — 40; 44 Participants — p=<0.001

Primary: Number of Patients With Intracranial Response — 3 participants

Primary: Maximum Tolerated Dose (MTD) of Hypofractionated Radiosurgery Defined as the Highest Dose Level Where a Grade 3 or Greater With an Attribution Score of ≥ 3 Develops in ≤…

Primary: The Number of Subjects Undergoing Resection Following SRS. — 11 Participants

Primary: Maximum Tolerated Dose of Five Fraction Stereotactic Radiotherapy — 35; 30 Gy

Primary: Local Control Rate (LCR) at 6 Months — 0.817 proportion of patients

Primary: 1-year Survival Rate — 31.8 Percentage of patients alive at 1 year

Primary: Objective Radiographic Tumor Response in Patients With Recurrent Solid Tumor Brain Metastases Treated With Bevacizumab — 2 Participants

Primary: Radiographic Response Assessed by Macdonald Criteria Every 2 Months — 3; 2; 4; 3 participants

Primary: Stereotactic Radiosurgery (SRS) Maximum-tolerated Dose (MTD) — 0; 0; 0; 0 Dose-limited toxicity (DLT) events

Primary: Cognitive Deterioration Free Survival Post-radiation in Patients Who Received SRS Compared to Patients Who Received WBRT — 3.0; 3.7 Months — p=<0.0001

Primary: Overall Survival — 4.0; 3.6 months — p=0.1862

Primary: Incidence of Chronic Neurotoxicity — 60; 85; 89 percentage of participants

Primary: Contrast to Noise Ratio — 3.2 Ratio — p=< 0.05

Primary: Assess the Need for Adaptations to the CALM Intervention as Measured by the Applicability of the 4 CALM Domains — 3.2; 4.0; 4.0; 3.5 score on a scale

Primary: Percentage of Participants With Distant Brain Failure (DBF) at One Year — 37 percentage of participants

Primary: The Number of Participants With Central Nervous System (CNS) Best Overall Response — 0; 0; 6; 9 Participants

Primary: Brain Metastasis Response Rate (BMRR) — 54.1; 75 percentage of participants

Primary: Overall Response in the Brain by mRECIST — 17; 31; 6; 11 participants

Primary: Percent Change in Delayed Recall at 4 Months as Measured by the Hopkins Verbal Learning Test-Revised (HVLT-R) — 7.0 percent change — p=<0.001

Primary: Tumor to Background Ratios (TBR) Post-imaging for All Lesions With PET Uptake — 8.25; 8.75 Ratio of PET SUV

Primary: Maximum Tolerated Dose (MTD) and Recommended Phase II Dose (RP2D) of Vorinostat and Radiotherapy in Patients With Brain Metastases. — 300 mg

Primary: Time to Neurocognitive Failure — 68.2; 59.3 percentage of participants — p=0.029